Compare HP Inc (HPQ) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs TG Therapeutics Inc — how do they compare? HP Inc trades at $30.2 (market cap $29.25B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: HP Inc is far larger — about 3.6× TG Therapeutics Inc's market cap, and HP Inc pays a 3.7% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 69 Days and TG Therapeutics Inc for 16 Days on average.
| HPQ | TGTX | |
|---|---|---|
Market Cap | $29.25B | $8.16B |
Volume | 10,025,806 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $35.48 | $59.06 |
52-Week Low | $18.20 | $26.94 |
Typical Hold Time | 69 Days | 16 Days |
Enterprise Value | $35.42B | $8.37B |
Dividend Yield | 3.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $32.44, up 0.62% with a bullish technical signal. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid cash flow generation of $460M in 2025. Valuation appears attractive with P/E of 12.38 and P/S of 0.51, though the company faces headwinds from projected PC market declines in 2027.
HPQ offers value characteristics with reasonable valuation metrics and consistent dividend payments, but faces significant business risks from PC market contraction. Analyst sentiment is mixed with 30.8% buy ratings versus 53.8% holds, reflecting uncertainty about growth prospects amid industry challenges.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
